Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI
NCT02859727 · Pharming Technologies B.V. · PHASE2/PHASE3 · terminated · last registry update 2026-03-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “All participant have transitioned to commercial product or compassionate use.” | – | Registry record, Pharming Technologies B.V. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CD within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-30Results posted on the registry: Alliance for Clinical Trials in Oncology, Abemaciclib + PI3K Inhibitor paxalisib (NCT03994796)
- 2026-10-27Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Ipilimumab (NCT04317105)
- 2026-10-21Results posted on the registry: Incyte Biosciences Japan GK, tafasitamab + lenalidomide (NCT04661007)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-03-03Results posted on the registry: National Cancer Institute (NCI), Rituximab + Copanlisib (NCT03789240)
- 2026-02-27Results posted on the registry: Massachusetts General Hospital, Umbralisib + Rituximab (NCT03919175)
- 2026-02-27Also stopped (terminated): Massachusetts General Hospital, Umbralisib + Rituximab (NCT03919175)
- 2026-02-13Also stopped (suspended): Dana-Farber Cancer Institute, Palbociclib + Gedatolisib (NCT03065062)
- 2026-02-04Also stopped (terminated): Incyte Corporation, tafasitamab + parsaclisib (NCT04809467)
- 2026-02-04Also stopped (terminated): Centre Hospitalier Universitaire Dijon, Taselisib (GDC0032) + Taselisib (GDC0032) (NCT03290092)
- 2026-01-29Results posted on the registry: Incyte Corporation, tafasitamab + parsaclisib (NCT04809467)
- 2026-01-09Also stopped (terminated): M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
- 2026-01-06Also stopped (terminated): H. Lee Moffitt Cancer Center and Research Institute, Umbralisib (NCT04163718)
- 2025-12-02Also stopped (terminated): Henan Cancer Hospital, Parsaclisib + Chidamide (NCT05083208)
- 2025-11-03Also stopped (terminated): Incyte Corporation, parsaclisinib + placebo (NCT05073458)
- 2025-10-21Also stopped (terminated): Incyte Corporation, parsaclisib + ruxolitinib (NCT04551066)
- 2025-10-02Also stopped (terminated): Incyte Corporation, parsaclisib + ruxolitinib (NCT04551053)
- 2025-10-01Also stopped (terminated): National Cancer Institute (NCI), Copanlisib + Pertuzumab (NCT04108858)
- 2025-09-08Also stopped (terminated): Institut Curie, PF-05212384 (NCT02438761)
- 2025-08-24Phase 3 first posted: Dizal Pharmaceuticals, DZD8586 + Bendamustine (NCT07139873)
- 2025-08-08Also stopped (terminated): Fondazione Italiana Linfomi - ETS, Copanlisib (NCT04433182)
- 2025-08-03Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Durvalumab (NCT03842228)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
- 2025-07-22Also stopped (terminated): Cancer Trials Ireland, Copanlisib + Trastuzumab emtansine (NCT04042051)
- 2025-07-11Results posted on the registry: M.D. Anderson Cancer Center, Copanlisib + fulvestrant (NCT05082025)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision